Eupraxia Pharmaceuticals to Showcase EP-104GI Data at DDW 2026
Event summary
- Eupraxia Pharmaceuticals will present 4 abstracts at the Digestive Disease Week Annual Meeting, May 2-5, 2026.
- Oral presentation on May 3, 2026, will detail 36-week histological improvements in EoE patients treated with EP-104GI.
- Poster presentations on May 5, 2026, will cover endoscopic, dysphagia, and dosing data from the RESOLVE trial.
- Virtual investor event on May 4, 2026, will feature KOLs discussing esophageal stricture treatment and EP-104GI's potential.
The big picture
Eupraxia's presentation at DDW 2026 comes as the biotech sector increasingly focuses on targeted drug delivery solutions. The company's Diffusphere technology aims to address unmet needs in gastrointestinal and inflammatory diseases, positioning it in a competitive landscape with other innovative delivery platforms. The RESOLVE trial data could be a key differentiator if it demonstrates sustained efficacy and safety advantages over current treatments.
What we're watching
- Clinical Efficacy
- Whether EP-104GI's 36-week histological improvements can position it as a long-term EoE treatment.
- Market Differentiation
- How Eupraxia's Diffusphere technology will compete against existing and emerging EoE therapies.
- Investor Sentiment
- The impact of DDW 2026 data presentations on Eupraxia's valuation and investor confidence.
Related topics